Could investing in the pharmaceutical giant pay off over the next five years? I think so, and here is why. AbbVie has a ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

High induction doses of risankizumab — at double and quadruple the approved 150 mg dose — produced rapid and durable skin clearance in patients with moderate-to-severe plaque psoriasis while ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...